← FDA DRUG APPROVALS

FDA ANDA · ANDA087799

TRIAMCINOLONE ACETONIDE

Sponsor: ACTAVIS MID ATLANTIC

APPLICATION
ANDA087799
TYPE
ANDA
ORIGINAL APPROVAL
1982-06-07
LATEST ACTION
2001-05-30
ROUTE
TOPICAL
DOSAGE FORM
OINTMENT
MARKETING STATUS
Discontinued

Products

TRIAMCINOLONE ACETONIDEDiscontinued
TRIAMCINOLONE ACETONIDE 0.1% · OINTMENT · TOPICAL

Approval history

2001-05-30Manufacturing (CMC) · Supplement 17AP
2000-12-29Manufacturing (CMC) · Supplement 16AP
1996-09-10Manufacturing (CMC) · Supplement 12AP
1996-09-10Manufacturing (CMC) · Supplement 15AP
1996-09-10Manufacturing (CMC) · Supplement 13AP
1996-09-10Manufacturing (CMC) · Supplement 11AP
1996-06-28Manufacturing (CMC) · Supplement 14AP
1996-02-07Manufacturing (CMC) · Supplement 10AP
1995-02-03Manufacturing (CMC) · Supplement 9AP
1995-02-03Manufacturing (CMC) · Supplement 8AP
1991-02-19Labeling · Supplement 5AP
1989-07-26Manufacturing (CMC) · Supplement 7AP
1989-07-26Manufacturing (CMC) · Supplement 6AP
1985-12-20Manufacturing (CMC) · Supplement 3AP
1983-03-08Manufacturing (CMC) · Supplement 2AP
1982-06-07OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →